Osteoarthritis risk associated with denosumab in adults with osteoporosis: A target trial emulation
Clicks: 10
ID: 321986
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
2.7
/100
10 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #13 of 116 articles by views in journal of bone and mineral research : the official journal of the american society for bone and mineral research
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Denosumab, a well-established osteoporosis treatment, has demonstrated potential bone- and cartilage-protective effects in preclinical and early trials. However, it remains unclear whether these promising findings extend to osteoarthritis prevention in weight-bearing joints and broader real-world osteoporotic populations. We compared osteoarthritis incidence between denosumab and oral bisphosphonates in adults aged 50 years or older with osteoporosis using a sequential nested target trial emulation with propensity score matching based on longitudinal health insurance claims data from Japan collected between 2015 and 2024. Two target comparisons were conducted: one compared new users of denosumab with new users of oral bisphosphonates, and the other compared patients who switched from oral bisphosphonates to denosumab with those who continued oral bisphosphonates. The primary outcome was osteoarthritis incidence. Secondary outcomes included joint-specific osteoarthritis (knee, hip, and hand) over 3 years. The absolute risk reduction (ARR) and relative risk (RR) at 3 years were estimated using a Kaplan–Meier estimator in both the per-protocol and intention-to-treat analyses. In the per-protocol analyses, the ARR for incident osteoarthritis was 2.0% (95% confidence interval [CI], 1.1%–3.2%) in the new-user comparison, with an RR of 0.83 (95% CI, 0.73–0.91), and 0.9% (95% CI, –0.2% to 2.8%) in the switch-continue comparison, with an RR of 0.92 (95% CI, 0.76–1.02). In the intention-to-treat analyses, the corresponding ARR was 1.9% (95% CI, 1.3%–3.3%) in the new-user comparison, with an RR of 0.84 (95% CI, 0.73–0.89), and 1.2% (95% CI, –0.2% to 2.7%) in the switch-continue comparison, with an RR of 0.89 (95% CI, 0.77–1.02). Denosumab initiation was associated with a modestly lower risk of incident osteoarthritis than oral bisphosphonate initiation, although the association was weaker in the switch-continue comparison.
| Reference Key |
openalex_W7170039992
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Masaki Hatano, Yuya Kimura, Akira Okada, Hisatoshi Ishikura, Takeyuki Tanaka, Taku Saito, Sakae Tanaka, Hideo Yasunaga |
| Journal | journal of bone and mineral research : the official journal of the american society for bone and mineral research |
| Year | 2026 |
| DOI |
10.1093/jbmr/zjag113
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.